click enter text
full postview beat rais larg
quiet quarter sell-off high expect
report financi result tuesday open
compani in-lin revenu beat ep guidanc
rais narrow
bodi report full analysi
addit detail us/eu drug compani
cover see recent initi report oct global
trade fundament data
upsid target
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday market open
report result in-lin revenu actual vs consensu beat ep
rais narrow guidanc
overal perspect overal decent quarter soft certain diabet program
surpris price competit categori one account top line receiv
mani question rewind result top-lin posit yesterday give increment
color note like make trulic label admittedli seem far away
overal import new ground broken lli confer call addit disclosur beyond
press releas increment natur like share high-expect
consensu buy trade high valuat despit continu execut well recent re-
initi market-perform rate downgrad prior rate call lli higher valuat
context face headwind like ciali loe possibl flattish year
term sale ep exhibit
revenu in-lin vs consensu growth primarili driven
trulic lesser extent taltz basaglar
non-gaap ep higher vs consensu beat partli attribut
lower expect tax rate vs
trulic compar consensu growth driven primarili
taltz in-lin vs consensu increas demand us partial
off-set lower realiz price ex-u volum increas new launch
humalog lower vs consensu softer revenu attribut
term guidanc exhibit
revenu bottom rang rais increas vs prior
non-gaap ep rais vs prior
oper expens ms rais vs prior maintain
oie unchang
tax decreas vs prior
long-term guidanc reiter revenu growth compound-annual-growth-rate reiter
oper margin least
page
pipelin noth materi new press releas slide recal yesterday news trulic toplin
posit rewind cv outcom trial demonstr reduct mace attrit two
alzheim diseas program investor expect high narrow upsid
option offer invest area also continu show develop risk
diseas area despit advanc understand diseas patholog
revenu decreas ep increas
revenu estim decreas ep estim increas
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas repres peer
pt decreas target multipl lower price target
base new higher ep contract partli reflect broader market contract
rewind result present ada preced set predominantli
oral chugai
 addit color rewind share press releas
 commerci impact rewind wont specul label might get note help
class
 rewind see label label updat probabl
 rewind could mean commerci would comment
 product came expect like humalog basaglar detail share
humalog see price declin y/i see mid-sd price eros averag
longer period time basaglar price erod ensur access medicar part
 lli latest think fda potenti deem biosimilar insulin
interchang substitut brand say like year away immin
requir appropri studi allow
page
 barrier use usag go forward class overal grow high-sd percent
see new patient start acceler encourag new guidelin ada easd
signific improv also tailwind improv access
exclud major plan competitor data affirm cv safeti class
 launch second brand jardianc better access medicar say
 hope achiev oral rel competit note yet
clinic non-peptid agonist small molecul approach better bioavail
could confer clinic benefit
 dual glp/gip trial attempt improv toler timelin
dose use titrat manag toler detail share yet
 ex-u growth opportun rel us bigger futur hold
note growth percent think play favor time
 jardianc type diabet file work bi next step regulatori say
 decent monotherapi activ comment outlook excit
program data come lung look high low renal see
monotherapi activ still work develop program
day provid updat molecul
 outlook class seem slow verzenio adjuv timelin pull
forward one year ct gov say ye seen growth moder across class nbrx
rate verzenio high teen flat per lli slide reson prescrib certain
patient subgroup get clear benefit patient liver met adjuv timelin enrol
well enrol expect result adjuv market size metastat
 lartruvo long-term outlook uptak remain strong market leader segment market
 limit us uptak talk access physician interest eu product remain
fastest volum grower portfolio us give sampl in-offic mask uptak
get favor feedback speed onset note three phase studi addit indic ad
lupu alopecia areata
page
 outlook growth given new competit come class continu like outlook given
pend indic expans market access bit less cosentyx still robust
cluster headach btd submit y/e
 outlook emgal migrain franchis overal remain excit categori
reduct data label cluster import approv therapi
 cluster headach commerci opportun describ detail made gener
combin termin lli select compound
 tanezumab efficaci seem wane outlook difficult make cross-trial comparison
earlier studi overal still excit efficaci note still need discharg safeti
risk class come larg studi report wolf comment
continu mix view pipelin drug continu proactiv suggest import
safeti hurdl still need cross could forewarn opioid crisi realli
us phenomenon rais question mind ex-u commerci opportun
 drop still aliv decis drop bace base
seen across field actual seem see increas rate clinic deterior
bace therapi also saw increas rate psychiatr drug question
find brain shrinkag mri remain excit program
new guidanc includ neg come elanco minor interest
 headwinds/tailwind main headwind ciali loe tailwind includ volum uplift
variou new product launch anoth top line headwind chang donut hole provis move
 side robust portfolio lead spend growth
mirikizumab armo asset sg spend redirect ciali forteo other new
brand like emgal expect manag pretti flat level overal excit
 one-tim boost volum basaglar contribut
call one-tim event per se
 list price outlook talk donut hole step-up exposur
co-pay accumul provid price assumpt analyst
page
meet expect increment step donut hole discuss
previous co-pay accumul signific exposur overal impact across
industri tend lower side
exhibit show compani report actual result vs estim consensu
page
exhibit result vs wr estim consensu
page
exhibit summar lli financi guidanc vs estim
exhibit guidanc vs wr estim old new
exhibit captur chang forecast
exhibit chang wr model
page
oldnewprior wolf bgross marginapprox bother meffect tax rateapprox guidancewr estimatesp revenu margin exp margin incom
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak tanezumab anti-ngf pain galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
